AzTrials
AzTrials

Primary LymhedemaLYMPHOQOLNCT01922635

Validation of Metrological Properties of Lymphoqol

A study testing Valadation of the metrological properties of questionnaire of quality of life in people with Primary Lymhedema, run by University Hospital, Montpellier at 1 site in France.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The constitutional lymphœdema is a rare disease with an annual incidence before the age of 20 years considered at 1,15/100 000. This chronic, incurable disease without hiring directly the prognosis for survival, alter the body image imposing a "visible" deformity and of which the treatment which aims at reducing and… Read more about this study

Who is it for?
Ages 6 to 25 years
Conditions the study is for
Primary Lymhedema
What is being tested?
Valadation of the metrological properties of questionnaire of quality of life
Could I receive a placebo?
No, everyone receives an active treatment
How many people
37 participants
Where
1 siteFrance
Study dates
Jul 2013to 13 Jan 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 25 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Primary lymphedema, stage 2 or 3 ISL

Who cannot join

  • Primary lymphedema stage 1, secondary lymphedema, Minimum 6 years, maximum 25

Trial locations and contacts

1 site in 1 country.

France1 site
  • CHU Montpellier

    Montpellier, Herault, 34295

Other trials in France

About this study

Official title: Validation of Metrological Properties of Questionnaire of Quality of Life LYMPHOQOL

The constitutional lymphœdema is a rare disease with an annual incidence before the age of 20 years considered at 1,15/100 000. This chronic, incurable disease without hiring directly the prognosis for survival, alter the body image imposing a "visible" deformity and of which the treatment which aims at reducing and at stabilizing the physical deformation is binding and expensive. The lymphœdema is a crippling disease of the child. As such, it rings on the everyday life of the child and on the family environment. This question is all the more important, that all the studies show that the success of the treatment bases on the compliance in the concentration and in the care of hygiene. The parameters of the success of these treatments at the child are not known.

Read the detailed description

In the literature we find no specific information on the psychic and social repercussions of the lymphœdema for the child who is affected. If the psychic and social repercussions of the secondary lymphœdema in the breast cancer are well known, very few things are it on those of the primary lymphœdema. Some studies estimate globally the quality of life of the patients with a lymphœdema whatever is the origin and the etiologie. These studies of money groups suggest that the psychic difficulties and of therapeutic care are not identical. A single study approaches the specific question of the lymphœdema of the child by focusing on the real-life experience of expanding child of a primary lymphœdema.The construction and the validation of a tool measuring the quality of life of the children and the young adults affected by lymphœdema congenital appears as a starting point. A tool which would first of all allow to make the current situation for the regional level, and then can envisage national actions common. According to recent studies, the evolution of the lymphoedema is different according to the forms of initial clinical expression of the lymphoedema, we wish we can thus know during this study the impact of these various clinical forms on the quality of life of the patients. A genetic collection will be realized for that purpose (genetic research).

Being tested
Valadation of the metrological properties of questionnaire of quality of life
Keywords
Primary lymphedema quality of life, genetic research

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Valadation of the metrological properties of questionnaire of quality of lifeOther

Study groups in NCT01922635
Study groupRoleWhat they receive
1OtherNot described
Receives: Other: Valadation of the metrological properties of questionnaire of quality of life

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Validation of the metrological properties of questionnaire of quality of life LYMPHOQOL

    Measured: 3 Years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Aug 2013 (estimated)
  2. Study startJul 2013
  3. Primary completion13 Jan 2022
  4. Study completion13 Jan 2022

Why it stopped: Modification the study with a new questionnaire was not successful.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
37 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01922635
Sponsor's protocol ID
8967
Acronym
LYMPHOQOL
Status last verified
May 2023
First submitted
12 Aug 2013
Last updated
18 May 2023
Results posted
No
Data monitoring committee
No

Publications

  • Quere I, Stasi E, Mestre S, Roessler J, Roccatello D, Moffatt C. International Camps for Children with Lymphedema and Lymphatic Anomalies: When Education Links with Psychosocial Research. Lymphat Res Biol. 2021 Feb;19(1):36-40. doi: 10.1089/lrb.2020.0095.

    PubMed 33625888

Questions about this trial

What is this clinical trial studying?

A study testing Valadation of the metrological properties of questionnaire of quality of life in people with Primary Lymhedema, run by University Hospital, Montpellier at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 18 May 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Modification the study with a new questionnaire was not successful.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Validation of the metrological properties of questionnaire of quality of life LYMPHOQOL (time frame: 3 Years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01922635, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in